Lenz & Staehelin advises Bain Capital Private Equity and Cinven

On February 8, 2021, Bain Capital Private Equity and Cinven have entered into definitive agreements to acquire Lonza Specialty Ingredients, a division of Lonza AG, for a total enterprise value of CHF 4.2 billion. The transaction is expected to close in the second half of 2021, subject to customary closing conditions.

The team 

Lenz & Staehelin advises Bain Capital Private Equity and Cinven on this transaction. The team includes partners Tino Gaberthüel (Corporate / M&A – pictured), Beat Kühni (Real Estate), Marcel Tranchet (Finance), Astrid Waser (Competition) and Pascal Hinny (Tax) as well as Eric Meier, Alex Wille, Xavier Grivel and Lisa Moser (all Corporate and M&A), Tobias Weber (Real Estate), Roland Fischer, Kevin MacCabe (both Finance), Anja Affolter Marino (Employment/Pension), Leo Rusterholz (IT, Data Protection, Transitional Services), Lukas Aebi (Tax) and David Hitz (IP).

Headquartered in Basel, LSI has approximately 2,800 employees, 11 R&D centres and 17 manufacturing sites across the world. LSI is a global provider of specialty chemicals for microbial control solutions, used to eliminate or control harmful and unwanted micro-organisms. The business also produces a range of other specialty chemicals, centred around its unique production facility in Switzerland. The business serves approx. 5,300 customers across a wide range of end-markets.